S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Boston Scientific And Johnson & Johnson: Stents Make A Comeback?

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

http://www.bloomberg.com/apps/news?pid=20601087&sid=ajZ2lVrqeb2I&refer=homeA study out fo Sweden may help the flagging fortunes of the stent businesses at Boston Scientific (BSX) and Johnsohn & Johnson (JNJ). Several pieces of research had indicated that drug-coated stents could cause cloating and health risks.

According to Bloomberg, "The new findings, presented at the European Society of Cardiology meeting in Vienna, show patients getting the drug- coated stents weren’t more likely to die or have a heart attack than those given the older, bare-metal stents." The use of blood thinners may have aided the results.

A number of doctors remain unconvinced.

Share of BSX has been badly hurt by the controversy of stent safety. The company is looking at selling division to save money and some Wall St. analysts think the company may run into cash flow problems while it pays down its huge debt, brought on when it bought medical device company  Guidant.

BSX shares were above $28 in late 2005. Today they trade below $13.

Douglas A. McIntyre

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)
Jeremy Phillips |

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)
"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan
Jeremy Phillips |

"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan

Continue Reading

Douglas A. McIntyre |

Coated Stent Sales Stay In Reverse

Coated stents cost more than un-coated ones. Putting the drugs onto the coated stents must add expense. But, that means…
Douglas A. McIntyre |

New Study Hammer Johnson & Johnson Stents

Johnson & Johnson’s (JNJ) new drug coated stent did not cut it. The experimental drug-coated stent failed to meet its…
Douglas A. McIntyre |

Witch Doctors And Stents (BSX)(JNJ)

No matter how many studies the medical community does, it cannot come up with a solid opinion for or against…
Douglas A. McIntyre |

Send The Stents To Europe, They’ll Try Anything

Boston Scientific (BSX) is beginning to market its new drug-coated stent in Europe. After the firestorm of criticism in the…
Douglas A. McIntyre |

Boston Scientific (BSX): The Stent Business Can’t Get More Confused

After reports last week that drug-coated stents posed little risk to heart patients, a new survey shows that  "patients given…
Douglas A. McIntyre |

Stent Safety Issues at the FDA….Hogwash

Stock Tickers: BSX, JNJ, ANPI, SRDX, CONR, BMY, SNY, ABT, MDT The FDA review of stents should not change the…
Douglas A. McIntyre |

No Signs Of Intelligent Life At Boston Scientific

Virtually nothing has gone right at Boston Scientific (BSX) since it bought rival Guidant in a bidding war with Johnson & Johnson (JNJ)…
Douglas A. McIntyre |

For Boston Scientific And JNJ, The Stent Stats Get Worse

"William O’Neill, dean of clinical affairs at University of Miami’sMiller School of Medicine, says stent-patient traffic is beginning topick up…
Douglas A. McIntyre |

A Reprieve For Boston Scientific (BSX)

Put back the crash carts. Boston Scientific is up and walking. A sharp decline in coated drug stents, brought on…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618